Ropeginterferon alfa-2b

Phase 3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Primary Myelofibrosis

Conditions

Primary Myelofibrosis, Myeloproliferative Neoplasm

Trial Timeline

Jul 18, 2025 → Sep 30, 2028

NCT ID

NCT06468033

About Ropeginterferon alfa-2b

Ropeginterferon alfa-2b is a phase 3 stage product being developed by PharmaEssentia for Primary Myelofibrosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06468033. Target conditions include Primary Myelofibrosis, Myeloproliferative Neoplasm.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07468916	Phase 2	Recruiting	Mar 29, 2026	Mar 30, 2032	Atypical Chronic Myeloid Leukemia
NCT06290765	Approved	Recruiting	Feb 1, 2026	Jun 30, 2027	Polycythemia Vera
NCT07047885	Phase 1	Recruiting	Aug 27, 2025	Jun 1, 2028	Cutaneous T Cell Lymphoma
NCT06468033	Phase 3	Recruiting	Jul 18, 2025	Sep 30, 2028	Primary Myelofibrosis
NCT05485948	Phase 2	Active	Oct 8, 2021	Jul 1, 2027	Polycythemia Vera
NCT03546465	Phase 1	Completed	May 7, 2018	Jul 15, 2019	Healthy Volunteers

Competing Products

20 competing products in Primary Myelofibrosis

See all competitors

Product	Company	Stage	Hype Score
Unfractionated heparin	Sinopharm	Pre-clinical	22
azenosertib	Zentalis Pharmaceuticals	Phase 2	44
Latanoprost plus adjunctive glaucoma medication	Sight Sciences	Approved	77
REN001	OnKure Therapeutics	Phase 1	25
Mavodelpar + Placebo	OnKure Therapeutics	Phase 2	44
REN001	OnKure Therapeutics	Phase 2/3	57
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, Placebo	Skye Bioscience	Phase 2	44
Rituximab + Methotrexate + Cytarabine Injection	Celltrion	Phase 2	52
Rituximab, lenalidomide	Celltrion	Phase 2	52
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RIS	Chugai Pharmaceutical	Phase 3	77
CS-3150	Daiichi Sankyo	Pre-clinical	23
Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin	Daiichi Sankyo	Pre-clinical	23
Bempedoic acid 180 mg tablet	Daiichi Sankyo	Approved	85
Combination of bempedoic acid and ezetimibe	Daiichi Sankyo	Pre-clinical	23
DS-8201a + T-DM1	Daiichi Sankyo	Phase 3	77
Bempedoic acid and/or its fixed dose combination with ezetimibe	Daiichi Sankyo	Pre-clinical	23
Roxadustat + Placebo	Astellas Pharma	Phase 3	77
Enzalutamide + Exemestane	Astellas Pharma	Phase 2	52
Bocidelpar + Placebo	Astellas Pharma	Phase 2	52
Methotrexate + Ibrutinib + Temozolomide	Sun Pharmaceutical	Phase 2	52

Other Products from PharmaEssentia

Ropeginterferon alfa-2bApproved

Pegylated-Proline-Interferon alpha-2b in a Pre-filled PenPhase 3

P1101 + Ribavirin + PEG-Intron + RibavirinPhase 3

Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT)Phase 3

P1101 (Ropeginterferon alfa-2b)Phase 3